User contributions for Rithish Nimmagadda
Jump to navigation
Jump to search
2 June 2024
- 23:1923:19, 2 June 2024 diff hist +14 User:Rithish Nimmagadda →Pages Authored/Co-authored/Collaborated current
- 23:1923:19, 2 June 2024 diff hist +11,398 N Iptacopa Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=iptacopa |aOrAn=a |drugClass=complement factor B inhibitor. |indicationType=treatment |indication=adults with paroxysmal nocturnal hemoglobinuria (PNH). |hasBlackBoxWarning=Yes |adverseReactions=Most common adverse reactions in adults with PNH (incidence ≥10%) were headache, nasopharyngitis, diarrhea, abdominal pain, bacterial infection, viral infection, nausea, and rash. |blackBoxWarningTitle=Serious Infecti..." current
21 May 2024
- 22:0122:01, 21 May 2024 diff hist +1,587 Vonoprazan, amoxicillin, and clarithromycin No edit summary current
- 21:5821:58, 21 May 2024 diff hist −12 User:Rithish Nimmagadda →Pages Authored/Co-authored/Collaborated
- 18:3518:35, 21 May 2024 diff hist +47 User:Rithish Nimmagadda →Pages Authored/Co-authored/Collaborated
- 18:3518:35, 21 May 2024 diff hist +14 User:Rithish Nimmagadda →Pages Authored/Co-authored/Collaborated
- 18:3318:33, 21 May 2024 diff hist +7,024 N Vonoprazan, amoxicillin, and clarithromycin Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=vonoprazan, amoxicillin, and clarithromycin |aOrAn=a |drugClass=Potassium-competitive acid blocker |indicationType=treatment |indication=- erosive esophagitis (all grades) and relief of heartburn associated with erosive esophagitis in adults. ,Helicobacter pylori Infection |adverseReactions=-Common adverse reactions (≥2%) with vonoprazan when used for healing of erosive esophagitis: gastritis, diarrhea, abdom..."
- 17:0417:04, 21 May 2024 diff hist +19 User:Rithish Nimmagadda →Pages Authored/Co-authored/Collaborated
- 16:5916:59, 21 May 2024 diff hist +4,566 N Pirtobrutinib Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=pirtobrutinib |aOrAn=an |drugClass=noncovalent (reversible) inhibitor of Bruton's tyrosine kinase (BTK). |indicationType=treatment |indication=elapsed or refractory MCL in adults who have received at least 2 lines of prior systemic therapy, including a BTK inhibitor; designated an orphan drug by FDA for treatment of MCL and also in treatment of CLL or SLL in adults who have received at least 2 prior lines of th..." current
- 00:1200:12, 21 May 2024 diff hist +313 Elacestrant No edit summary current
- 00:1000:10, 21 May 2024 diff hist +17 User:Rithish Nimmagadda →Pages Authored/Co-authored/Collaborated
- 00:0900:09, 21 May 2024 diff hist +2,860 N Elacestrant Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=elacestrant |aOrAn=an |drugClass=estrogen receptor antagonist |indicationType=treatment |indication=estrogen receptor (ER)-positive, human epidermal growth factor receptor type 2 (HER2)-negative, estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer that has progressed following ≥1 line of endocrine-based therapy in postmenopausal women or adult men. |fdaLIADAdult=Dosage of elacestrant hydro..."
20 May 2024
- 23:0723:07, 20 May 2024 diff hist +25 User:Rithish Nimmagadda →Pages Authored/Co-authored/Collaborated
- 23:0723:07, 20 May 2024 diff hist +7,709 N Velmanase alfa-tycv Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=velmanase alfa-tycv |aOrAn=an |drugClass=recombinant preparation of human lysosomal alpha-mannosidase |indicationType=treatment |indication=non-central nervous system manifestations of alpha-mannosidosis in adult and pediatric patients |adverseReactions=Most common adverse reactions (incidence >20%) are hypersensitivity reactions (including anaphylaxis), nasopharyngitis, pyrexia, headache, and arthralgia. |blac..." current
- 20:3620:36, 20 May 2024 diff hist −296 Retifanlimab-dlwr No edit summary current
- 20:3320:33, 20 May 2024 diff hist +86 Retifanlimab-dlwr No edit summary
- 20:3220:32, 20 May 2024 diff hist +23 User:Rithish Nimmagadda →Pages Authored/Co-authored/Collaborated
- 20:3120:31, 20 May 2024 diff hist +8,964 N Retifanlimab-dlwr Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=retifanlimab-dlwr |aOrAn=an |indicationType=treatment |indication=adults with metastatic or recurrent locally advanced Merkel cell carcinoma . Indication approved under accelerated approval based on tumor response rate and duration of response; continued approval may be contingent upon verification and description of clinical benefit in confirmatory trials. |adverseReactions=Adverse effects (≥10%): fatigue..."
- 20:1820:18, 20 May 2024 diff hist +14 User:Rithish Nimmagadda →Pages Authored/Co-authored/Collaborated
- 20:1820:18, 20 May 2024 diff hist +3,936 N Tofersen Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=tofersen |aOrAn=an |drugClass=antisense oligonucleotide |indicationType=treatment |indication=amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene. |adverseReactions=he most common adverse reactions (≥ 10% of patients treated with tofersen and greater than placebo) were pain, fatigue, arthralgia, increased CSF white blood cell, and myalgia. |fdaLIADAdult=..." current
18 May 2024
- 16:0216:02, 18 May 2024 diff hist +18 User:Rithish Nimmagadda →Pages Authored/Co-authored/Collaborated
- 16:0216:02, 18 May 2024 diff hist +22 Ritlecitinib No edit summary current
- 16:0116:01, 18 May 2024 diff hist +10,106 N Ritlecitinib Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=ritlecitinib |aOrAn=a |drugClass=janus kinase 3 (JAK3) inhibitor and also an inhibitor of the tyrosine kinase |indicationType=treatment |indication=severe alopecia areata in adults and adolescents 12 years of age and older |hasBlackBoxWarning=Yes |adverseReactions=Most common adverse reactions (incidence ≥1%) are headache, diarrhea, acne, rash, urticaria, folliculitis, pyrexia, atopic dermatitis, dizziness, i..."
17 May 2024
- 17:2117:21, 17 May 2024 diff hist +17 User:Rithish Nimmagadda →Pages Authored/Co-authored/Collaborated
- 17:2117:21, 17 May 2024 diff hist +8,825 N Quizartinib Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=quizartinib |aOrAn=a |drugClass=a kinase inhibitor |indicationType=treatment |indication=adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 internal tandem duplication (ITD)-positive as detected by an FDA-approved test. |hasBlackBoxWarning=Yes |adverseReactions=The most common (>20%) adverse reactions, including laboratory abnormalities, are decreased lymphocytes, decreased potassium,..." current
- 16:5816:58, 17 May 2024 diff hist +15 User:Rithish Nimmagadda →Pages Authored/Co-authored/Collaborated
- 16:4016:40, 17 May 2024 diff hist +2,182 N Lotilaner Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=lotilaner |aOrAn=a |drugClass=gamma-aminobutyric acid (GABA)-gated chloride channel inhibitor |indication=ectoparasiticide (anti-parasitic) indicated for the treatment of Demodex blepharitis |adverseReactions=The most common adverse reaction was instillation site stinging and burning |fdaLIADAdult=still one drop of lotilaner in each eye twice daily (approximately 12 hours apart) for 6 weeks. |fdaLIADPed=Safety..." current
- 15:4015:40, 17 May 2024 diff hist +17 User:Rithish Nimmagadda →Pages Authored/Co-authored/Collaborated
- 15:3815:38, 17 May 2024 diff hist +7,057 Bimekizumab No edit summary current
11 May 2024
- 22:3822:38, 11 May 2024 diff hist 0 User:Rithish Nimmagadda →Pages Authored/Co-authored/Collaborated
- 22:3422:34, 11 May 2024 diff hist +22 User:Rithish Nimmagadda →Pages Authored/Co-authored/Collaborated
- 22:3222:32, 11 May 2024 diff hist +13 Mirikizumab-mrkz No edit summary current
- 22:3122:31, 11 May 2024 diff hist 0 Mirikizumab-mrkz No edit summary
- 22:2622:26, 11 May 2024 diff hist +5,235 Mirikizumab-mrkz No edit summary
- 20:4820:48, 11 May 2024 diff hist −2 User:Rithish Nimmagadda →Pages Authored/Co-authored/Collaborated
- 20:4820:48, 11 May 2024 diff hist +16 User:Rithish Nimmagadda →Pages Authored/Co-authored/Collaborated
- 20:2120:21, 11 May 2024 diff hist +3,351 N Elfabrio Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=Pegunigalsidase Alfa-iwxj |drugClass=a hydrolytic lysosomal neutral glycosphingolipid-specific enzyme, is a pegylated recombinant form of human α-galactosidase A |indicationType=treatment |indication=ELFABRIO is an FDA approved drug that is used for treatment of adults with confirmed Fabry disease. |hasBlackBoxWarning=Yes |adverseReactions=Most common adverse reactions (≥15%) are infusion-associated reactio..." current
- 19:3619:36, 11 May 2024 diff hist +44 N Exxua Created page with "{{DrugProjectFormSinglePage |authorTag={{ }}" current
9 May 2024
- 14:3514:35, 9 May 2024 diff hist +123 User:Rithish Nimmagadda →Education
- 14:3214:32, 9 May 2024 diff hist +11,409 Epcoritamab-bysp No edit summary current
- 13:1413:14, 9 May 2024 diff hist +4 Epcoritamab-bysp No edit summary
- 13:1013:10, 9 May 2024 diff hist +46 N Epcoritamab-bysp Created page with "{{DrugProjectFormSinglePage |authorTag=VSRN }}"
8 May 2024
- 14:4414:44, 8 May 2024 diff hist +81 N Template:VSRN Created page with "Rithish Nimmagadda,MBBS.[mailto:rithishnvs@gmail.com]" current
- 14:3014:30, 8 May 2024 diff hist +2 FRUZAQLA No edit summary current Tag: Visual edit
- 14:2514:25, 8 May 2024 diff hist +35 FRUZAQLA No edit summary
- 14:2114:21, 8 May 2024 diff hist −9 User:Rithish Nimmagadda →Your Name
- 14:2114:21, 8 May 2024 diff hist +9 User:Rithish Nimmagadda →Your Name
- 14:2014:20, 8 May 2024 diff hist +362 N User:Rithish Nimmagadda Created page with "<nowiki> __NOTOC__ ==Your Name== ''' Rithish Nimmagadda, MBBS Research scholar <br />Contact:945-278-1660 <br /> Email: rithishnvs@gmail.com [mailto:rithishnvs@gmail.com]<br /> ==Current Position== * research scholar (list chapters here)<br /> ==Education== Medical Degree from Kamineni Academy of Medical sciences and research centre , Hyderabad , India"
- 14:1014:10, 8 May 2024 diff hist +9,092 N FRUZAQLA Created page with "{{DrugProjectFormSinglePage |aOrAn=a |indicationType=treatment |indication=FRUZAQLA is a kinase inhibitor indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine‑, oxaliplatin‑, and irinotecan‑based chemotherapy, an anti‑VEGF therapy, and, if RAS wild‑type and medically appropriate, an anti-EGFR therapy. |adverseReactions=Most common adverse reactions ( are hypertension, palma..."
- 13:3213:32, 8 May 2024 diff hist +49 N Fruzaqla Created page with "{{DrugProjectFormSinglePage |authorTag=rithish }}" current